Calithera Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-06-01
- Employees
- 10
- Market Cap
- $487
- Website
- http://www.calithera.com
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 41
- Registration Number
- NCT02834247
- Locations
- 🇺🇸
Fox Chase, Philadelphia, Pennsylvania, United States
🇺🇸Mary Crowley Research Centers, Dallas, Texas, United States
🇺🇸US Oncology, Fairfax, Virginia, United States
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 118
- Registration Number
- NCT02771626
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 141
- Registration Number
- NCT02756364
- Locations
- 🇺🇸
New England Cancer Specialists, Scarborough, Maine, United States
🇺🇸Texas Oncology, P.A., Dallas, Texas, United States
🇺🇸St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare, Fullerton, California, United States
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 43
- Registration Number
- NCT02323113
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT02197572
Study of the Glutaminase Inhibitor CB-839 in Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 43
- Registration Number
- NCT02071927
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
- Conditions
- Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung CancerRenal Cell CarcinomaMesotheliomaSuccinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal TumorsTumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 MutationsFumarate Hydratase (FH)-Deficient TumorsSuccinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)Tumors Harboring Amplifications in the cMyc Gene
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 210
- Registration Number
- NCT02071862
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 25
- Registration Number
- NCT02071888
- Locations
- 🇺🇸
Winship Cancer Institute of Emory School of Medicine, Atlanta, Georgia, United States
🇺🇸John Theruer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 118
- Registration Number
- NCT02049957
- Locations
- 🇺🇸
Henry Ford Medical Center, Novi, Michigan, United States
🇺🇸Texas Oncology, P.A. - Tyler, Tyler, Texas, United States
🇫🇷Institut Sainte Catherine, Avignon, Vaculuse, France
A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 143
- Registration Number
- NCT02000934
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇮🇹Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Italy